The chart below shows how NCPL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NCPL sees a +2.71% change in stock price 10 days leading up to the earnings, and a -12.11% change 10 days following the report. On the earnings day itself, the stock moves by -1.20%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Broker-Dealer Approval Milestone: Netcapital Securities, Inc. received FINRA approval, allowing it to operate as a broker-dealer, which is a significant milestone for the company.
Expansion of Revenue Opportunities: The establishment of Netcapital Securities enables the company to handle private placements of securities, support companies raising equity capital under Reg A and Reg D, and partner with other broker-dealers, expanding revenue opportunities.
Strategic Partnership Development: GenOn Neuroscience, Inc. has engaged Netcapital Securities for broker-dealer and administrative services, indicating early success in leveraging the new subsidiary's capabilities.
Cautious Optimism for Growth: Management remains cautiously optimistic about future growth despite current market uncertainties, reflecting a positive outlook for the company's strategic direction.
Negative
Revenue Decline Analysis: Revenues for Q3 2025 decreased by approximately 85% to $152,682 compared to $1,042,793 in Q3 2024, indicating a significant decline in financial performance.
Revenue Decline Analysis: The decline in revenue was attributed to the lack of consulting service revenue for equity securities, which was $862,346 in Q3 2024, highlighting a loss of a key revenue stream.
Worsening Net Loss: Net loss for Q3 2025 was approximately $3,006,537, compared to a net loss of approximately $2.2 million in the same period last year, showing worsening financial health.
Increased Operating Loss: Operating loss increased to $1,687,692 in Q3 2025 from $1,205,157 in Q3 2024, indicating deteriorating operational efficiency.
Impairment Charge Reported: An impairment charge of $1.3 million for one of the portfolio companies was reported, reflecting potential issues with asset valuation and management.
Improved Net Loss Per Share: Net loss per share was reported at $1.57 for Q3 2025, compared to a loss of $13.60 per share in the prior year, suggesting a significant drop in shareholder value.
Netcapital Inc. (NCPL) Q3 2025 Earnings Call Transcript
NCPL.O
5.43%